Granules Pharmaceuticals Initiates Class III Recall for Amphetamine Mixed Salts Due to Impurity Failures
Granules Pharmaceuticals Inc. has initiated a Class III recall (D-0672-2025) for 11,909 bottles of Dextroamphetamine/Amphetamine mixed salts extended-release capsules from its Chantilly, VA facility. This voluntary, firm-initiated recall, distributed nationwide, stems from the product failing impurity and degradation specifications. Procurement and regulatory teams must assess supply chain exposure and monitor Granules' remediation efforts closely.
FDA Mandates Class III Recall for Granules Pharmaceuticals' Amphetamine Mixed Salts
Granules Pharmaceuticals Inc. has initiated a Class III recall, designated D-0672-2025, for its Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules, 20 mg. This recall, formally initiated on August 28, 2025, and classified by the FDA on September 24, 2025, affects 11,909 bottles of the product, specifically Lot GPC250179A with an expiration date of June 22, 2027. The primary reason for this action is the product's failure to meet established impurity and degradation specifications. For procurement directors, this signifies an immediate disruption in the supply of a critical central nervous system stimulant. The Class III classification indicates that while the use of or exposure to the product is not likely to cause serious adverse health consequences, it still represents a significant quality deviation that necessitates removal from the market. Regulatory affairs heads must recognize that this voluntary, firm-initiated recall, distributed nationwide in the USA, underscores a lapse in Good Manufacturing Practices (GMP) that could trigger heightened FDA scrutiny on Granules' future product applications and manufacturing processes. Businesses relying on Granules Pharmaceuticals for any Dextroamphetamine/Amphetamine mixed salts or other controlled substances must immediately quarantine affected stock and initiate return procedures, while simultaneously evaluating the broader implications for their supply chain resilience.
Quality Control Lapses at Granules' Chantilly, VA Facility Impact Supply
The recalled Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules were manufactured by Granules Pharmaceuticals Inc. at its facility located at 3701 Concorde Pkwy, Chantilly, VA 20151-1126. The failure to meet impurity and degradation specifications points to potential deficiencies in the manufacturing process, raw material quality control, or stability testing protocols at this specific site. For supply chain VPs, this event highlights the critical importance of robust supplier qualification and ongoing monitoring, particularly for active pharmaceutical ingredients (APIs) and finished dosage forms of controlled substances. The recall of 11,909 bottles, distributed nationwide across the USA, directly impacts market availability for the 20 mg strength of this essential medication. While the specific application number ANDA217027 is linked to this product, the incident raises questions about the overall quality management system at the Chantilly facility. Business development executives should note that such quality issues can erode market confidence and create opportunities for competitors. Any company sourcing APIs or finished products from Granules Pharmaceuticals, especially from their Chantilly, VA operation, must conduct an immediate risk assessment to understand their exposure and verify the integrity of other products supplied by this manufacturer.
Mitigating Supply Chain Risk for Dextroamphetamine/Amphetamine Formulations
The nationwide distribution of the recalled Dextroamphetamine/Amphetamine mixed salts extended-release capsules means that pharmacies, distributors, and healthcare providers across the United States are directly impacted. Procurement directors must ensure their inventory management systems are updated to identify and segregate Lot GPC250179A immediately. The failure in impurity/degredation specifications for a controlled substance like Dextroamphetamine/Amphetamine mixed salts, which addresses conditions such as ADHD and narcolepsy, can lead to localized shortages and patient care disruptions if not managed effectively. Supply chain VPs should view this incident as a critical reminder to diversify their sourcing strategies for essential medications, particularly those with complex manufacturing requirements or high regulatory scrutiny. Relying on a single supplier for such critical products introduces significant vulnerability. The product's multiple NDC codes (e.g., 70010-029, 70010-032-01) indicate various strengths and packaging configurations, suggesting a broader manufacturing capability by Granules Pharmaceuticals for this class of drug. This recall necessitates a comprehensive review of all products sourced from Granules, not just the specific recalled lot, to proactively identify and mitigate potential future supply interruptions.
Navigating Alternative Sourcing in the Controlled Substances Market
Given the recall of Granules Pharmaceuticals' Dextroamphetamine/Amphetamine mixed salts, procurement teams must urgently explore alternative suppliers to ensure continuity of supply for this critical medication. Identifying and qualifying new manufacturers for controlled substances presents unique challenges due to stringent regulatory requirements, including DEA quotas and specific licensing. While the available intelligence does not name specific alternative suppliers for this particular formulation, the strategic imperative is clear: companies must maintain a robust roster of pre-qualified or readily qualifiable manufacturers. This involves identifying geographically diverse suppliers to mitigate regional risks, assessing their regulatory compliance history, and understanding their production capacities. Qualification timelines for new suppliers of controlled substances can be extensive, often spanning 12-24 months, encompassing audits, analytical method transfers, stability studies, and regulatory filings. Therefore, business development executives should prioritize partnerships with manufacturers demonstrating consistent quality and robust regulatory compliance. Proactive engagement with contract manufacturing organizations (CMOs) or other API suppliers with established track records in amphetamine-based products is crucial. This incident underscores that a reactive approach to supplier diversification for controlled substances is insufficient and can lead to significant market disadvantages and patient impact.
Granules Pharmaceuticals' Regulatory Standing and Future Scrutiny
The Class III recall of Dextroamphetamine/Amphetamine mixed salts extended-release capsules by Granules Pharmaceuticals Inc. will undoubtedly place the company under increased regulatory scrutiny from the FDA. While the provided intelligence does not detail a history of prior Warning Letters, 483s, or Import Alerts for Granules, this recall serves as a significant regulatory event. Regulatory affairs heads should anticipate that the FDA will closely monitor Granules' corrective and preventive actions (CAPA) plan to address the root cause of the failed impurity/degradation specifications. The agency will expect a thorough investigation, effective remediation, and verification of these actions. Failure to adequately address these issues could escalate to more severe regulatory actions, including potential Warning Letters, increased inspection frequency, or even restrictions on future product approvals from the Chantilly, VA facility. For business development executives, this means that any new product launches or market expansions involving Granules Pharmaceuticals may face delays or require additional due diligence regarding their manufacturing quality. Companies partnering with Granules must demand full transparency on their remediation progress and assess the potential impact on their own regulatory submissions and market access strategies. This event signals a critical period for Granules Pharmaceuticals to reinforce its commitment to quality and regulatory compliance.